342 related articles for article (PubMed ID: 17267497)
1. Identification of amino acid residues in APOBEC3G required for regulation by human immunodeficiency virus type 1 Vif and Virion encapsidation.
Huthoff H; Malim MH
J Virol; 2007 Apr; 81(8):3807-15. PubMed ID: 17267497
[TBL] [Abstract][Full Text] [Related]
2. Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F.
Russell RA; Pathak VK
J Virol; 2007 Aug; 81(15):8201-10. PubMed ID: 17522216
[TBL] [Abstract][Full Text] [Related]
3. Differential requirement for conserved tryptophans in human immunodeficiency virus type 1 Vif for the selective suppression of APOBEC3G and APOBEC3F.
Tian C; Yu X; Zhang W; Wang T; Xu R; Yu XF
J Virol; 2006 Mar; 80(6):3112-5. PubMed ID: 16501124
[TBL] [Abstract][Full Text] [Related]
4. Characterization of conserved motifs in HIV-1 Vif required for APOBEC3G and APOBEC3F interaction.
He Z; Zhang W; Chen G; Xu R; Yu XF
J Mol Biol; 2008 Sep; 381(4):1000-11. PubMed ID: 18619467
[TBL] [Abstract][Full Text] [Related]
5. A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion.
Xu H; Svarovskaia ES; Barr R; Zhang Y; Khan MA; Strebel K; Pathak VK
Proc Natl Acad Sci U S A; 2004 Apr; 101(15):5652-7. PubMed ID: 15054139
[TBL] [Abstract][Full Text] [Related]
6. Human immunodeficiency virus type 1 Vif inhibits packaging and antiviral activity of a degradation-resistant APOBEC3G variant.
Opi S; Kao S; Goila-Gaur R; Khan MA; Miyagi E; Takeuchi H; Strebel K
J Virol; 2007 Aug; 81(15):8236-46. PubMed ID: 17522211
[TBL] [Abstract][Full Text] [Related]
7. Identification of a novel WxSLVK motif in the N terminus of human immunodeficiency virus and simian immunodeficiency virus Vif that is critical for APOBEC3G and APOBEC3F neutralization.
Dang Y; Wang X; Zhou T; York IA; Zheng YH
J Virol; 2009 Sep; 83(17):8544-52. PubMed ID: 19535447
[TBL] [Abstract][Full Text] [Related]
8. Influence of primate lentiviral Vif and proteasome inhibitors on human immunodeficiency virus type 1 virion packaging of APOBEC3G.
Liu B; Yu X; Luo K; Yu Y; Yu XF
J Virol; 2004 Feb; 78(4):2072-81. PubMed ID: 14747572
[TBL] [Abstract][Full Text] [Related]
9. HIV-1 Vif can directly inhibit apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3G-mediated cytidine deamination by using a single amino acid interaction and without protein degradation.
Santa-Marta M; da Silva FA; Fonseca AM; Goncalves J
J Biol Chem; 2005 Mar; 280(10):8765-75. PubMed ID: 15611076
[TBL] [Abstract][Full Text] [Related]
10. HIV-1 Vif inhibits G to A hypermutations catalyzed by virus-encapsidated APOBEC3G to maintain HIV-1 infectivity.
Wang Y; Kinlock BL; Shao Q; Turner TM; Liu B
Retrovirology; 2014 Oct; 11():89. PubMed ID: 25304135
[TBL] [Abstract][Full Text] [Related]
11. New insights into the role of Vif in HIV-1 replication.
Schröfelbauer B; Yu Q; Landau NR
AIDS Rev; 2004; 6(1):34-9. PubMed ID: 15168739
[TBL] [Abstract][Full Text] [Related]
12. Multifaceted counter-APOBEC3G mechanisms employed by HIV-1 Vif.
Britan-Rosich E; Nowarski R; Kotler M
J Mol Biol; 2011 Jul; 410(5):1065-76. PubMed ID: 21763507
[TBL] [Abstract][Full Text] [Related]
13. Mechanism of Enhanced HIV Restriction by Virion Coencapsidated Cytidine Deaminases APOBEC3F and APOBEC3G.
Ara A; Love RP; Follack TB; Ahmed KA; Adolph MB; Chelico L
J Virol; 2017 Feb; 91(3):. PubMed ID: 27881650
[TBL] [Abstract][Full Text] [Related]
14. Regulation of APOBEC3 proteins by a novel YXXL motif in human immunodeficiency virus type 1 Vif and simian immunodeficiency virus SIVagm Vif.
Pery E; Rajendran KS; Brazier AJ; Gabuzda D
J Virol; 2009 Mar; 83(5):2374-81. PubMed ID: 19109396
[TBL] [Abstract][Full Text] [Related]
15. A patch of positively charged amino acids surrounding the human immunodeficiency virus type 1 Vif SLVx4Yx9Y motif influences its interaction with APOBEC3G.
Chen G; He Z; Wang T; Xu R; Yu XF
J Virol; 2009 Sep; 83(17):8674-82. PubMed ID: 19535450
[TBL] [Abstract][Full Text] [Related]
16. APOBEC3G targets human T-cell leukemia virus type 1.
Sasada A; Takaori-Kondo A; Shirakawa K; Kobayashi M; Abudu A; Hishizawa M; Imada K; Tanaka Y; Uchiyama T
Retrovirology; 2005 May; 2():32. PubMed ID: 15943885
[TBL] [Abstract][Full Text] [Related]
17. The anti-HIV-1 editing enzyme APOBEC3G binds HIV-1 RNA and messenger RNAs that shuttle between polysomes and stress granules.
Kozak SL; Marin M; Rose KM; Bystrom C; Kabat D
J Biol Chem; 2006 Sep; 281(39):29105-19. PubMed ID: 16887808
[TBL] [Abstract][Full Text] [Related]
18. A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif).
Schröfelbauer B; Chen D; Landau NR
Proc Natl Acad Sci U S A; 2004 Mar; 101(11):3927-32. PubMed ID: 14978281
[TBL] [Abstract][Full Text] [Related]
19. Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif.
Mariani R; Chen D; Schröfelbauer B; Navarro F; König R; Bollman B; Münk C; Nymark-McMahon H; Landau NR
Cell; 2003 Jul; 114(1):21-31. PubMed ID: 12859895
[TBL] [Abstract][Full Text] [Related]
20. Signals in APOBEC3F N-terminal and C-terminal deaminase domains each contribute to encapsidation in HIV-1 virions and are both required for HIV-1 restriction.
Song C; Sutton L; Johnson ME; D'Aquila RT; Donahue JP
J Biol Chem; 2012 May; 287(20):16965-74. PubMed ID: 22451677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
